3-(Fmoc-氨甲基)苯甲酸 | 155369-11-2

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - FMOC-氨基酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: 3-(Fmoc-氨甲基)苯甲酸
• 中文别名: 3-(芴甲氧羰基-氨甲基)苯甲酸；3-(N-FMOC-氨甲基)苯甲酸
• 英文名称: 3-[(9H-fluoren-9-ylmethoxycarbonylamino)methyl]benzoic acid
• 英文别名: Fmoc-(3-aminomethyl)benzoic acid；3-(((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)methyl)benzoic acid
• CAS: 155369-11-2
• 化学式: C₂₃H₁₉NO₄
• 分子量: 373.408
• InChiKey: VODSFAVGEJUBHO-UHFFFAOYSA-N

物化性质

• 沸点：
  631.6±48.0 °C(Predicted)
• 密度：
  1.296±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 安全说明：
  S22,S24/25
• WGK Germany：
  3
• 海关编码：
  29242990
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Fmoc-3-aminomethylbenzoic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Fmoc-3-aminomethylbenzoic acid
CAS number: 155369-11-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C23H19NO4
Molecular weight: 373.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(Fmoc-氨甲基)苯甲酸 在 Rink amide resin 、 N,N'-二异丙基碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 N-[[5-chloro-1-(2-ethoxyethyl)-7-(pyrimidin-4-ylamino)pyrazolo[4,3-d]pyrimidin-3-yl]methyl]-N-methylacetamide
  参考文献：
  名称：

  [EN] DPP-IV INHIBITORS
  [FR] INHIBITEURS DE LA DPP-IV

  摘要：

  该发明涉及式(I)的化合物，其中Z-C(R1R2)-C(R3NH2)-C(R4R5)-X-N(R6R7)，其中Z，R1-7和X的含义如描述和权利要求中所述。所述化合物可用作DPP-IV抑制剂。该发明还涉及制备此类化合物以及其作为药物的生产和使用。

  公开号：

  WO2005095343A1
• 作为产物：
  描述：

  3-(氨甲基)苯甲酸 、 9-芴甲基-N-琥珀酰亚胺基碳酸酯 在 三乙胺 作用下， 以 水 、 乙腈 为溶剂， 反应 3.0h， 以68%的产率得到3-(Fmoc-氨甲基)苯甲酸
  参考文献：
  名称：

  基于抗体-抗原晶体结构的生物活性抗体模拟物的设计与合成

  摘要：

  我们使用 N9 唾液酸酶（抗原）-NC41（抗体）复合物的晶体结构设计了一种模拟大分子抗体结合功能的低分子量化合物。已经从能量精制的晶体复合物中分析了抗体和蛋白质抗原之间的识别成分。根据该分析，与抗原的活性位点环 368-370 直接接触的抗体结合表面上的四个氨基酸残基已被鉴定为贡献了蛋白质的大部分结合能。设计的目标化合物是一种受约束的环肽，模拟这些氨基酸的受体结合构象，已合成并发现可抑制 N9 唾液酸酶活性，Ki 为 1 x 10(-4) M。

  DOI：

  10.1021/ja00086a005

文献信息

• [EN] TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER<br/>[FR] PRODUITS RADIOPHARMACEUTIQUES CIBLÉS POUR LE DIAGNOSTIC ET LE TRAITEMENT DU CANCER DE LA PROSTATE
  申请人：BAYER AS

  公开号：WO2021013978A1

  公开（公告）日：2021-01-28

  A compound of general formula (I): wherein: n is 1, 2 or 3; R1, R2, R3 and R4, independently represent OH or Q; and 20 Q represents a tissue-targeting moeity selected from the group consisting of or a stereoisomer, a hydrate, a solvate, or a salt thereof, or a mixture of same, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said 25 compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of soft tissue diseases, as a sole agent or in combination with other active ingredients.

  通用式(I)的化合物：其中：n为1、2或3；R1、R2、R3和R4独立地代表OH或Q；Q代表从群组中选择的组织靶向基团，或其立体异构体、水合物、溶剂合物、盐或其混合物，制备所述化合物的方法，用于制备所述化合物的中间化合物，包含所述化合物的药物组合物和组合物，以及用于制造用于治疗或预防疾病的药物组合物的所述化合物的用途，特别是软组织疾病的治疗或预防，作为唯一药剂或与其他活性成分结合使用。
• [EN] EP2 RECEPTOR AGONISTS<br/>[FR] AGONISTES DES RECEPTEURS EP2
  申请人：PHARMAGENE LAB LTD

  公开号：WO2005080367A1

  公开（公告）日：2005-09-01

  A compound of Formula (I) or a salt, solvate and chemically protected form thereof, wherein: R5 is an optionally substituted C5-20 aryl or C4-20 alkyl group; A is selected from the group consisting of Formulae (Ai), (Aii), (Aiii) D is selected from Formulae (Di), (Dii), (Diii), (Div), (Dv) B is selected from the group consisting of Formulae (Bi), (Bii), (Biii), (Biv) (Bv).

  一个由化学式（I）或其盐、溶剂合物和化学保护形式组成的化合物，其中：R5是一个可选择取代的C5-20芳基或C4-20烷基基团；A选自由化合物（Ai）、（Aii）、（Aiii）组成的群；D选自由化合物（Di）、（Dii）、（Diii）、（Div）、（Dv）组成的群；B选自由化合物（Bi）、（Bii）、（Biii）、（Biv）、（Bv）组成的群。
• Identification of Shc Src Homology 2 Domain-Binding Peptoid−Peptide Hybrids
  作者：Won Jun Choi、Sung-Eun Kim、Andrew G. Stephen、Iwona Weidlich、Alessio Giubellino、Fa Liu、Karen M. Worthy、Lakshman Bindu、Matthew J. Fivash、Marc C. Nicklaus、Donald P. Bottaro、Robert J. Fisher、Terrence R. Burke

  DOI：10.1021/jm800789h

  日期：2009.3.26

  fluorescence anisotropy (FA) competition-based Shc Src homology 2 (SH2) domain-binding was established using the high affinity fluorescein isothiocyanate (FITC) containing peptide, FITC-NH-(CH2)4-CO-pY-Q-G-L-S-amide (8; Kd = 0.35 microM). Examination of a series of open-chain bis-alkenylamide containing peptides, prepared as ring-closing metathesis precursors, showed that the highest affinities were obtained

  使用含有高亲和力异硫氰酸荧光素 (FITC) 的肽 FITC-NH-(CH2)4-CO-pY-QGLS-酰胺，建立了基于荧光各向异性 (FA) 竞争的 Shc Src 同源性 2 (SH2) 结构域结合。 8；Kd = 0.35 microM)。对一系列含开链双链烯基酰胺的肽（作为闭环复分解前体制备）的检查表明，通过用 N α 取代的 Gly (NSG)“类肽”残基替换原始 Gly 残基获得了最高的亲和力。这提供了“Ac-pY-Q-[NSG]-L-酰胺”形式的拟肽-肽杂合体。根据 NSG 取代基的不同，这些杂交中的某些表现出比含 Gly 的亲本肽 (IC50 = 248 microM) 高 40 倍的 Shc SH2 结构域结合亲和力（例如，对于 N-高烯丙基类似物 50，IC50 = 6微）。据我们所知，这项工作代表了类肽-肽杂交体在 SH2 结构域结合拮抗剂设计中应用的第一个成功例子。这些结果可为
• Antagonists for treatment of CD/11CD18 adhesion receptor mediated disorders
  申请人：Burdick J. Daniel

  公开号：US20050203135A1

  公开（公告）日：2005-09-15

  Compounds of the general structure D-L-B-(AA), for example (A), that are useful for treating Mac-1 or LFA-1-mediated disorders such as inflammatory disorders, allergies, and autoimmune diseases are provided.

  提供了一些具有一般结构D-L-B-(AA)的化合物，例如(A)，这些化合物对治疗Mac-1或LFA-1介导的疾病如炎症性疾病、过敏和自身免疫疾病是有用的。
• Development of Low Molecular Weight HIV-1 Protease Dimerization Inhibitors
  作者：You Seok Hwang、Jean Chmielewski

  DOI：10.1021/jm049581j

  日期：2005.3.1

  The role of HIV protease in viral replication has made it a significant target for inhibition. The focus of our studies is to target the dimerization interface of HIV-1 protease because disruption of the dimer will inhibit enzymatic activity. The initial strategy began with cross-linked peptides derived from the interface of HIV protease. Herein we describe the design of a focused library of agents

  HIV蛋白酶在病毒复制中的作用使其成为重要的抑制靶标。我们研究的重点是针对HIV-1蛋白酶的二聚界面，因为二聚体的破坏会抑制酶的活性。最初的策略始于源自HIV蛋白酶界面的交联肽。在本文中，我们描述了基于HIV-1蛋白酶二聚化抑制作用的最小药效基团的试剂集中库的设计。